Sponsor

BIND Therapeutics

Clinical research sponsor

Published trials4

Recruiting shown0

Roles1

SourceClinicalTrials.gov

Clinical trials

4 shown

A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung CancerNCT02283320 · lead sponsor · 2014-09-01

COMPLETED

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy to Patients With Non-Small Cell Lung CancerNCT01792479 · lead sponsor · 2013-04-01

COMPLETED

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate CancerNCT01812746 · lead sponsor · 2013-04-01

COMPLETED

A Study of BIND-014 Given to Patients With Advanced or Metastatic CancerNCT01300533 · lead sponsor · 2011-01-01

COMPLETED

Sponsor roles

lead sponsor4

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.